AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04342104 — intervention group
Intervention type: OTHER
Intervention: Evaluate HACOR score effectivity in this patients
Description: Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
Study NCT02094716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Foam 4%
Description: Topical application, whole-body treatment
Study NCT00246701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Lovaza
Description: Simvastatin + Lovaza (omega-3-acid ethyl esters)
Study NCT02652260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine - Blinded
Description: A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
Study NCT02652260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine - Open-Label
Description: A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
Study NCT02652260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRIPLA^TM
Description: A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
Study NCT02652260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ATRIPLA™
Description: A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
Study NCT02652260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Doravirine, Tenofovir, Lamivudine
Description: A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
Study NCT02391181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Azad
Description: Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study NCT02391181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer®
Description: Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study NCT03576859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: Peripheral venous blood is collected before liver transplantation and after restoration of liver function
Study NCT04102995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone injection low dose
Description: Subcutaneous (SC) administration
Study NCT04102995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone injection high dose
Description: Subcutaneous (SC) administration
Study NCT04102995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subcutaneous (SC) administration
Study NCT03580980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol and ketamine
Description: intravenous paracetamol and ketamine followed by ketorolac
Study NCT03580980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal levobupivacaine
Description: an epidural injection of morphine and levobupivacaine through the caudal space
Study NCT03580980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient controlled analgesia by morphine
Study NCT02919254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet It Sport Shot
Description: Commercially available concentrated beetroot juice supplement intended for athletes.
Study NCT02919254 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fruit juice cordial containing negligible nitrate
Study NCT03562312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensive aerobe exercise
Description: Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
Study NCT03562312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low-intensive aerobe exercise
Description: Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
Study NCT04010877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
Description: Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
Study NCT01237613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artelon
Description: Artelon Tissue Reinforcement
Study NCT02094716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Permethrin Foam 4%
Description: Topical application, whole-body treatment
Study NCT02094716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Foam 5%
Description: Topical application, whole-body treatment
Study NCT02806960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study NCT02094716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Permethrin Foam 5%
Description: Topical application, whole-body treatment
Study NCT02094716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical application, whole-body treatment
Study NCT03282513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120 (Ivosidenib)
Description: Single 500 mg dose of AG-120 (Ivosidenib).
Study NCT03282513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-120 (Ivosidenib)
Description: Single 500 mg dose of AG-120 (Ivosidenib).
Study NCT03472781 — intervention group
Intervention type: OTHER
Intervention: No intervention. A retrospective case review
Description: No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
Study NCT04072081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Treatment of in suit coronary lesions with drug-coated balloon
Study NCT04072081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: Treatment of in suit coronary lesions with drug-eluting balloon
Study NCT02310919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose hCG plus FSH co-trigger
Description: Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
Study NCT00748592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study NCT00748592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study NCT00748592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study NCT00748592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study NCT03051386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEE Vaccine
Description: 0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
Study NCT03329053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EAPC Exercise Prescription (EXPERT) Tool
Description: During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication.
Study NCT03727932 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VioOne HIV Profile Supplemental Assay
Description: The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
Study NCT02602119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: Infusion of OTL38 prior to surgery
Study NCT03329053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardio-Care Lifestyle Counselling
Description: During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
Study NCT00991458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.010% eye drops
Description: Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Study NCT00991458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.005% eye drops
Description: Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Study NCT02310919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of hCG
Description: Standard dose of hCG (10,000 or 5,000 IU) trigger
Study NCT03821558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
Study NCT04411433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir (3200 mg + 1200 mg)
Description: Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator.
Study NCT04411433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir (3600 mg + 1600 mg)
Description: Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator.
Study NCT04411433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine
Description: Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator.
Study NCT04411433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin
Description: Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator.
Study NCT04411433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total).
Study NCT04411433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine combined with Azithromycin
Description: Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).
Study NCT02381418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study NCT00991458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle for Cyclosporine)
Description: Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Study NCT03336216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: specified does on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: specified does on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onivyde
Description: specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study NCT02933333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
Study NCT02504528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: house dust mites
Description: house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,......)
Study NCT01950221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: POMx
Description: POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
Study NCT01950221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04659642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: the drug is given 15 minutes before the estimated end of surgery
Study NCT02933333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
Study NCT02933333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF and G-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
Study NCT01769196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: 125 mg/mL single-dose vials administered subcutaneously once a week
Study NCT01769196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simtuzumab placebo
Description: Simtuzumab placebo single-dose vials administered subcutaneously once a week
Study NCT00438165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visitation by nurses from midway through pregnancy until child age 12
Study NCT05993910 — intervention group
Intervention type: OTHER
Intervention: Hyperthermie Register
Description: * die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: specified dose on specified days
Study NCT04659642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate Injection
Description: the drug is given 15 minutes before the estimated end of surgery
Study NCT04659642 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine and fentanyl
Description: the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: specified dose on specified day
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT03336216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Specified dose on specified days
Study NCT02719886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Estimation of fetal weight by ultrasound
Study NCT02719886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Estimation of fetal weight by ultrasound
Study NCT03385317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness